The Bull Case For ImmunityBio (IBRX) Could Change Following EMA’s Conditional Backing Of ANKTIVA Therapy

• ImmunityBio previously announced that the European Medicines Agency had recommended granting a conditional EU marketing authorization for ANKTIVA, in combination with BCG, to treat BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ based on a single-arm trial in 100 adults.
• This marks the first EMA-recommended immunotherapy for this form of bladder cancer that activates NK cells, T cells, and memory T cells, potentially offering an alternative to radical surgery for eligible patients.
• Next, we’ll examine how this conditional EMA backing for ANKTIVA, built on single-arm trial data, influences ImmunityBio’s investment narrative.

These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is ImmunityBio's Investment Narrative?

To own ImmunityBio today, you have to believe ANKTIVA can anchor a real commercial franchise while the company manages heavy losses and limited cash runway. The EMA’s conditional nod in bladder cancer, on top of existing U.S. approval, looks like a meaningful near term catalyst because it opens the door to EU pricing, reimbursement discussions and a clearer revenue ramp than analysts were modeling beforehand. At the same time, it does not erase key risks: ANKTIVA’s label is still based on a single arm trial, post marketing data will be closely watched and ImmunityBio remains reliant on external capital after recent equity dilution. With the share price still well below consensus targets even after a jump on the news, the investment case now turns on how quickly EU uptake can offset ongoing cash burn.

However, one crucial funding risk could still catch new shareholders off guard. ImmunityBio's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Ten Simply Wall St Community fair value estimates span roughly US$0.30 to nearly US$16, underscoring how far opinions diverge. Set that against ANKTIVA’s new EU catalyst and the company’s short cash runway, and you can see why many readers may want to compare multiple viewpoints before deciding what ImmunityBio’s future could look like.

Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth over 6x more than the current price!

Build Your Own ImmunityBio Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com